Results 301 to 310 of about 8,441,406 (356)

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis

Molecular Oncology, EarlyView.
This study highlights the potential of automated enumeration using the ACCEPT software to refine circulating tumor cell (CTC) detection in metastatic colorectal cancer (mCRC). The automated method demonstrates improved accuracy and reduced variability compared to the manual approach.
Michela De Meo, Marco Siringo, Alessandro Vici, Ann Zeuner, Orietta Gandini, Paola Gazzaniga, Chiara Nicolazzo   +6 more
wiley   +1 more source

T-Cell Prolymphocytic Leukaemia With Isolated Pulmonary Manifestation. [PDF]

Respirol Case Rep
Kobayashi Y, Tomioka H, Sakai R, Goto H.
europepmc   +1 more source

Biphasic behavior of T cell subsets reflects failure of early anti-myeloma response and leads to progressive T cell dysfunction. [PDF]

Neoplasia
Jadhav SS, Sharma V, Lion A, Efrat LK, Shaked I, Luboshits G, Firer MA.   +6 more
europepmc   +1 more source

Correction: Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin's lymphoma. [PDF]

J Immunother Cancer
europepmc   +1 more source

Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model. [PDF]

Blood Adv
Gamal W, Goedhart NB, Simon-Molas H, Mediavilla-Varela M, Uriepero-Palma A, Peters FS, Maharaj K, Chavez JC, Powers J, Obermayer A, Shaw TI, Conejo-Garcia JR, Rodriguez PC, Sahakian E, Pinilla-Ibarz J, Kater AP.   +15 more
europepmc   +1 more source

K12-ligand-based CAR T cell therapy for CD7-positive T cell malignancies. [PDF]

Mol Ther Oncol
Visser N, González-Corrales M, Álvarez-Freile J, Pruis MG, Rockstein L, Lourens HJ, Schuringa JJ, van Meerten T, Huls G, Bremer E.   +9 more
europepmc   +1 more source

Guardians of silence: transcriptional networks in T cell quiescence. [PDF]

Exp Mol Med
Choi JO, Seo Y, Hwang SS.
europepmc   +1 more source